Literature DB >> 8031045

Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations.

H E Takiff1, L Salazar, C Guerrero, W Philipp, W M Huang, B Kreiswirth, S T Cole, W R Jacobs, A Telenti.   

Abstract

The emergence of multidrug-resistant strains of Mycobacterium tuberculosis has resulted in increased interest in the fluoroquinolones (FQs) as antituberculosis agents. To investigate the frequency and mechanisms of FQ resistance in M. tuberculosis, we cloned and sequenced the wild-type gyrA and gyrB genes, which encode the A and B subunits of the DNA gyrase, respectively; DNA gyrase is the main target of the FQs. On the basis of the sequence information, we performed DNA amplification for sequencing and single-strand conformation polymorphism analysis to examine the presumed quinolone resistance regions of gyrA and gyrB from reference strains (n = 4) and clinical isolates (n = 55). Mutations in codons of gyrA analogous to those described in other FQ-resistant bacteria were identified in all isolates (n = 14) for which the ciprofloxacin MIC was > 2 micrograms/ml. In addition, we selected ciprofloxacin-resistant mutants of Mycobacterium bovis BCG and M. tuberculosis Erdman and H37ra. Spontaneously resistant mutants developed at a frequency of 1 in 10(7) to 10(8) at ciprofloxacin concentrations of 2 micrograms/ml, but no primary resistant colonies were selected at higher ciprofloxacin concentrations. Replating of those first-step mutants selected for mutants with high levels of resistance which harbored gyrA mutations similar to those found among clinical FQ-resistant isolates. The gyrA and gyrB sequence information will facilitate analysis of the mechanisms of resistance to drugs which target the gyrase and the implementation of rapid strategies for the estimation of FQ susceptibility in clinical M. tuberculosis isolates.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8031045      PMCID: PMC284541          DOI: 10.1128/AAC.38.4.773

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  31 in total

1.  gyrB mutations which confer coumarin resistance also affect DNA supercoiling and ATP hydrolysis by Escherichia coli DNA gyrase.

Authors:  A Contreras; A Maxwell
Journal:  Mol Microbiol       Date:  1992-06       Impact factor: 3.501

2.  Detection of gyrA gene mutations associated with ciprofloxacin resistance in methicillin-resistant Staphylococcus aureus: analysis by polymerase chain reaction and automated direct DNA sequencing.

Authors:  J J Goswitz; K E Willard; C E Fasching; L R Peterson
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

Review 3.  Genetic systems for mycobacteria.

Authors:  W R Jacobs; G V Kalpana; J D Cirillo; L Pascopella; S B Snapper; R A Udani; W Jones; R G Barletta; B R Bloom
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

4.  Conserved gene arrangement in the origin region of the Streptomyces coelicolor chromosome.

Authors:  M J Calcutt; F J Schmidt
Journal:  J Bacteriol       Date:  1992-05       Impact factor: 3.490

5.  Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis.

Authors:  A Telenti; F Marchesi; M Balz; F Bally; E C Böttger; T Bodmer
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

6.  Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology.

Authors:  J D van Embden; M D Cave; J T Crawford; J W Dale; K D Eisenach; B Gicquel; P Hermans; C Martin; R McAdam; T M Shinnick
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

7.  Characterization of an autonomously replicating region from the Streptomyces lividans chromosome.

Authors:  J Zakrzewska-Czerwińska; H Schrempf
Journal:  J Bacteriol       Date:  1992-04       Impact factor: 3.490

8.  Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple-drug-resistant bacilli.

Authors:  M A Fischl; G L Daikos; R B Uttamchandani; R B Poblete; J N Moreno; R R Reyes; A M Boota; L M Thompson; T J Cleary; S A Oldham
Journal:  Ann Intern Med       Date:  1992-08-01       Impact factor: 25.391

9.  Novel structure of the recA locus of Mycobacterium tuberculosis implies processing of the gene product.

Authors:  E O Davis; S G Sedgwick; M J Colston
Journal:  J Bacteriol       Date:  1991-09       Impact factor: 3.490

10.  A novel locus conferring fluoroquinolone resistance in Staphylococcus aureus.

Authors:  M Trucksis; J S Wolfson; D C Hooper
Journal:  J Bacteriol       Date:  1991-09       Impact factor: 3.490

View more
  152 in total

Review 1.  Molecular detection of antimicrobial resistance.

Authors:  A C Fluit; M R Visser; F J Schmitz
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

2.  Identification of mycobacterial species by PCR sequencing of quinolone resistance-determining regions of DNA gyrase genes.

Authors:  Jean-Noël Dauendorffer; Isabelle Guillemin; Alexandra Aubry; Chantal Truffot-Pernot; Wladimir Sougakoff; Vincent Jarlier; Emmanuelle Cambau
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

3.  Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination.

Authors:  S Sreevatsan; X Pan; K E Stockbauer; N D Connell; B N Kreiswirth; T S Whittam; J M Musser
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

4.  Sequence analysis of the gyrA and parC homologues of a wild-type strain of Vibrio parahaemolyticus and its fluoroquinolone-resistant mutants.

Authors:  J Okuda; E Hayakawa; M Nishibuchi; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

5.  GenoType MTBDRsl for molecular detection of second-line-drug and ethambutol resistance in Mycobacterium tuberculosis strains and clinical samples.

Authors:  A Lacoma; N García-Sierra; C Prat; J Maldonado; J Ruiz-Manzano; L Haba; P Gavin; S Samper; V Ausina; J Domínguez
Journal:  J Clin Microbiol       Date:  2011-11-09       Impact factor: 5.948

Review 6.  Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis.

Authors:  Karen R Jacobson; Dylan B Tierney; Christie Y Jeon; Carole D Mitnick; Megan B Murray
Journal:  Clin Infect Dis       Date:  2010-07-01       Impact factor: 9.079

7.  Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations.

Authors:  S Sreevatsan; K E Stockbauer; X Pan; B N Kreiswirth; S L Moghazeh; W R Jacobs; A Telenti; J M Musser
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

Review 8.  Genetics and pulmonary medicine. 5. Genetics of drug resistant tuberculosis.

Authors:  A Telenti
Journal:  Thorax       Date:  1998-09       Impact factor: 9.139

9.  Evolution of high-level ethambutol-resistant tuberculosis through interacting mutations in decaprenylphosphoryl-β-D-arabinose biosynthetic and utilization pathway genes.

Authors:  Hassan Safi; Subramanya Lingaraju; Anita Amin; Soyeon Kim; Marcus Jones; Michael Holmes; Michael McNeil; Scott N Peterson; Delphi Chatterjee; Robert Fleischmann; David Alland
Journal:  Nat Genet       Date:  2013-09-01       Impact factor: 38.330

10.  Genetic and phenotypic characterizations of drug-resistant Mycobacterium tuberculosis isolates in Cheonan, Korea.

Authors:  Jae-Sik Jeon; Jae Kyung Kim; Qute Choi; Jong Wan Kim
Journal:  J Clin Lab Anal       Date:  2018-02-03       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.